Table 6.

Univariate analysis of overall survival

Variable	N	Overall survival
		Median ± SE	95% CI	P-value
Sex				0.973
Male	125	34.00±2.97	28.16–39.83
Female	53	38.00±3.63	30.86–45.13
Age (years)				0.223
≤60	94	40.00±3.87	32.40–47.59
>60	84	32.00±1.13	29.77–34.22
Size (cm)				0.019
<3	44	46.00±5.20	35.79–56.20
3–5	54	34.00±1.83	30.40–37.51
>5	80	32.00±0.98	30.06–33.93
Borrmann				0.502
I	22	39.00±7.62	24.06–53.93
II	55	40.00±3.69	32.76–47.23
III	62	34.00±3.50	27.14–40.85
IV	39	31.00±1.77	27.51–34.48
Differentiation				0.107
High	12	40.00±6.06	28.11–51.88
Moderate	57	39.00±6.11	26.97–51.02
Poor	109	32.00±1.74	28.59–35.41
Depth of invasion				0.005
T1	16	46.00±8.66	29.01–62.98
T2	18	52.00 ±15.91	20.81–83.18
T3	67	35.00±4.60	25.98–44.01
T4	77	31.00±1.45	28.14–33.86
Lymph node metastasis				<0.001
N0	49	55.00±9.79	35.79–74.20
N1	36	43.00±7.80	27.22–58.78
N2	35	36.00±3.54	29.04–42.95
N3	58	29.00±2.53	24.03–33.96
Distant metastasis				<0.001
M0	138	40.00±3.91	32.32–47.67
M1	40	29.00±1.57	25.91–32.08
TNM stage				<0.001
I	21	49.00±3.21	42.69–66.71
II	34	45.00±5.83	33.57–56.42
III	83	34.00±2.27	29.53–38.41
IV	40	29.00±1.57	25.91–32.08
E-cadherin				<0.001
High	60	54.00±2.08	48.52–59.48
Low	118	29.00±1.45	26.15–31.85
TGF-β1				<0.001
High	111	31.00±1.31	28.41–33.58
Low	67	50.00±5.26	39.68–60.31
CD163				<0.001
High	94	28.00±2.20	23.68–32.31
Low	84	46.00±3.05	40.01–51.98

Abbreviations: SE, standard error; CI, confidence interval; TNM, tumor node metastasis; TGF-β1, transforming growth factor-β1.